Subscribe
shutterstock_1904205580_rarrarorro
rarrarorro / Shutterstock.com
19 October 2021GenericsAlex Baldwin

AstraZeneca wins patent infringement case over Farxiga generic

AstraZeneca has convinced a federal court to uphold challenged claims of a patent related to its diabetes drug Farxiga (dapagliflozin).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
AstraZeneca inks $730m licensing deal for rare heart disease treatment
11 January 2022   Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.
Americas
AbbVie and AstraZeneca settle cancer drug patent suits
25 October 2019   AbbVie and AstraZeneca reached a settlement over patent suits involving their rival cancer drugs earlier this week, after nearly two years of litigation.
Americas
Acorda and AstraZeneca claim victory over Mylan
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Biotechnology
AstraZeneca inks $730m licensing deal for rare heart disease treatment
11 January 2022   Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.
Americas
AbbVie and AstraZeneca settle cancer drug patent suits
25 October 2019   AbbVie and AstraZeneca reached a settlement over patent suits involving their rival cancer drugs earlier this week, after nearly two years of litigation.
Americas
Acorda and AstraZeneca claim victory over Mylan
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.

More on this story

Biotechnology
AstraZeneca inks $730m licensing deal for rare heart disease treatment
11 January 2022   Alexion, AstraZeneca’s rare disease group, has entered into an exclusive licensing agreement with Neurimmune AG for NI006, an antibody in development for the treatment of the heart condition, transthyretin amyloid cardiomyopathy.
Americas
AbbVie and AstraZeneca settle cancer drug patent suits
25 October 2019   AbbVie and AstraZeneca reached a settlement over patent suits involving their rival cancer drugs earlier this week, after nearly two years of litigation.
Americas
Acorda and AstraZeneca claim victory over Mylan
21 March 2016   The US Court of Appeals for the Federal Circuit has rejected Mylan’s attempt to dismiss two patent lawsuits on the grounds of lack of personal jurisdiction.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB